The triad in current neuroblastoma challenges: Targeting antigens, enhancing effective cytotoxicity and accurate 3D in vitro modelling.

Neuroblastoma is an embryonic tumour originating from neural crest cells and accounts for nearly 15 % of all childhood cancer deaths. Despite the implementation of intense multimodal therapy for neuroblastoma, half of the high-risk cohort will relapse with metastatic foci resistant to conventional therapies. There is an urgent need for novel precision medicine approaches to improve patient survival and ensure healthy post-treatment lives for these children.

In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma.

Neuroblastoma is the most common solid extracranial tumour in children. Despite major advances in available therapies, children with drug-resistant and/or recurrent neuroblastoma have a dismal outlook with 5-year survival rates of less than 20%. Therefore, tackling relapsed tumour biology by developing and characterising clinically relevant models is a priority in finding targetable vulnerability in neuroblastoma.

Application of Photogrammetry in Biomedical Science.

Photogrammetry is an upcoming technology in biomedical science as it provides a non-invasive and cost-effective alternative to established 3D imaging techniques such as computed tomography. This review introduces the photogrammetry approaches currently used for digital 3D reconstruction in biomedical science and discusses their suitability for different applications. It aims to offer the reader a better understanding of photogrammetry as a 3D reconstruction technique and to provide some guidance on how to choose the appropriate photogrammetry approach for their research area (including single- versus multi-camera setups, structure-from-motion versus conventional photogrammetry and macro- versus microphotogrammetry) as well as guidance on how to obtain high-quality data.